瑞巴派特联合益生菌辅助标准四联疗法对Hp相关性十二指肠溃疡患者的疗效研究
|
摘要
目的探讨瑞巴派特联合益生菌辅助标准四联疗法对Hp相关性十二指肠溃疡患者的疗效及安全性。方法选取我院2016年1月至2018年12月收治的Hp相关性十二指肠溃疡患者共110例,以随机抽签法分为对照组(55例)和观察组(55例),两组均采用标准四联疗法治疗,其中对照组给予益生菌治疗,观察组在对照组的基础上加用瑞巴派特辅助治疗,比较两组患者溃疡愈合率、Hp根除率、治疗前后腹痛评分、溃疡面积、血清学实验室指标水平及不良反应发生率。结果观察组溃疡愈合率和Hp根除率均显著高于对照组(P<0.05);观察组治疗后腹痛评分和溃疡面积均显著小于对照组及治疗前(P<0.05);观察组治疗后IgA及IgG水平均显著优于对照组及治疗前(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞巴派特联合益生菌辅助标准四联疗法治疗Hp相关性十二指肠溃疡可有效提高Hp根除效果,促进溃疡愈合,缓解疼痛症状,调节IgA和IgG水平,且安全性良好。
Objective To investigate the efficacy of rebamipide combined with probiotics assisting standard quadruple therapy on patients with Hp-related duodenal ulcer.Methods Totally 110 patients with Hp-related duodenal ulcer were chosen from January 2016 to December 2018 in our hospital and were randomly divided into 2 groups,including control group(n=55) with probiotics and observation group(n=55) with rebamipide combined with probiotics assisting standard quadruple therapy;the ulcer healing rate,Hp eradication rate,abdominal pain score,ulcer area,and serological laboratory index levels before and after treatment and the adverse reactions between the two groups were compared.Results The ulcer healing rate and Hp eradication rate of observation group were higher than those of control group(P<0.05).The abdominal pain score and ulcer area of observation group after treatment were less than those of control group and before treatment(P<0.05).The levels of IgA and IgG of observation group after treatment were better than those of control group and before treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Rebamipide combined with probiotics assisting standard quadruple therapy in the treatment of patients with Hp-related duodenal ulcer can efficiently improve the eradication effects of Hp,promote ulcer healing,relieve pain symptoms,and regulate the levels of IgA and IgG with satisfactory safety.
Objective To investigate the efficacy of rebamipide combined with probiotics assisting standard quadruple therapy on patients with Hp-related duodenal ulcer.Methods Totally 110 patients with Hp-related duodenal ulcer were chosen from January 2016 to December 2018 in our hospital and were randomly divided into 2 groups,including control group(n=55) with probiotics and observation group(n=55) with rebamipide combined with probiotics assisting standard quadruple therapy;the ulcer healing rate,Hp eradication rate,abdominal pain score,ulcer area,and serological laboratory index levels before and after treatment and the adverse reactions between the two groups were compared.Results The ulcer healing rate and Hp eradication rate of observation group were higher than those of control group(P<0.05).The abdominal pain score and ulcer area of observation group after treatment were less than those of control group and before treatment(P<0.05).The levels of IgA and IgG of observation group after treatment were better than those of control group and before treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Rebamipide combined with probiotics assisting standard quadruple therapy in the treatment of patients with Hp-related duodenal ulcer can efficiently improve the eradication effects of Hp,promote ulcer healing,relieve pain symptoms,and regulate the levels of IgA and IgG with satisfactory safety.
引文
[1] Liu H,Chen YT,Wang R,et al.Helicobacter pylori infection,atrophic gastritis,and pancreatic cancer risk:a meta-analysis of prospective epidemiologic studies[J].Medicine,2017,96(33):e7811.
[2] Lanas A,Chan FK.Peptic ulcer disease [J].Lancet,2017,390(10094):613-624.
[3] Khonche A,Biglarian O,Panahi Y,et al.Adjunctive therapy with curcumin for peptic ulcer:a randomized controlled trial [J].Drug Res (Stuttg),2016,66(8):444-448.
[4] Drini M.Peptic ulcer disease and non-steroidal anti-inflammatory drugs [J].Aust Prescr,2017,40(3):91-93.
[5] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-511.
[6] Khasag O,Boldbaatar G,Tegshee T,et al.The prevalence of helicobacter pylori infection and other risk factors among Mongolian dyspeptic patients who have a high incidence and mortality rate of gastric cancer [J].Gut Pathogens,2018,10(3):14-20.
[7] Abadi ATB.Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization [J].World J Gastroenterol,2017,23(35):6379-6384.
[8] Yakovenko EP,Agafonova NA,Ivanov AN,et al.The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract [J].Ter Arkh,2016,88(4):88-92.
[9] Sgourakis G,Chatzidakis G,Poulou A,et al.High-dose vs.low-dose proton pump inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer.A meta-analysis and meta-regression analysis [J].Turk J Gastroenterol,2018,29(1):22-31.
[10] Sverdén E,Brusselaers N,Wahlin K,et al.Time latencies of helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer,ulcer adverse events,and gastric cancer:a population-based cohort study [J].Gastrointest Endosc,2018,88(2):242-250.
[11] Khatoon J,Prasad KN,Prakash RR,et al.Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer [J].Br J Biomed Sci,2017,74(3):121-126..
[12] Andreev DN,Dicheva DT,Maev IV.Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice [J].Ter Arkh,2017,89(2):84-90.
[13] Andreev DN,Maev IV,Dicheva DT,et al.Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection:a prospective randomized comparative study [J].Ter Arkh,2018,90(8):27-32.
[14] Gadsby JE,Nipper AT,Faircloth HA,et al.Toll-like receptor and related cytokine mRNA expression in bovine corpora lutea during the oestrous cycle and pregnancy [J].Reprod Domest Anim,2017,52(3):495-504.
[15] Albalushi MS,Said EA,Hasson SS,et al.High levels of IgA antibodies to helicobacter pylori among Omani women during pregnancy and after delivery [J].Iran J Immunol,2016,13(2):114-123.
[2] Lanas A,Chan FK.Peptic ulcer disease [J].Lancet,2017,390(10094):613-624.
[3] Khonche A,Biglarian O,Panahi Y,et al.Adjunctive therapy with curcumin for peptic ulcer:a randomized controlled trial [J].Drug Res (Stuttg),2016,66(8):444-448.
[4] Drini M.Peptic ulcer disease and non-steroidal anti-inflammatory drugs [J].Aust Prescr,2017,40(3):91-93.
[5] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-511.
[6] Khasag O,Boldbaatar G,Tegshee T,et al.The prevalence of helicobacter pylori infection and other risk factors among Mongolian dyspeptic patients who have a high incidence and mortality rate of gastric cancer [J].Gut Pathogens,2018,10(3):14-20.
[7] Abadi ATB.Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization [J].World J Gastroenterol,2017,23(35):6379-6384.
[8] Yakovenko EP,Agafonova NA,Ivanov AN,et al.The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract [J].Ter Arkh,2016,88(4):88-92.
[9] Sgourakis G,Chatzidakis G,Poulou A,et al.High-dose vs.low-dose proton pump inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer.A meta-analysis and meta-regression analysis [J].Turk J Gastroenterol,2018,29(1):22-31.
[10] Sverdén E,Brusselaers N,Wahlin K,et al.Time latencies of helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer,ulcer adverse events,and gastric cancer:a population-based cohort study [J].Gastrointest Endosc,2018,88(2):242-250.
[11] Khatoon J,Prasad KN,Prakash RR,et al.Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer [J].Br J Biomed Sci,2017,74(3):121-126..
[12] Andreev DN,Dicheva DT,Maev IV.Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice [J].Ter Arkh,2017,89(2):84-90.
[13] Andreev DN,Maev IV,Dicheva DT,et al.Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection:a prospective randomized comparative study [J].Ter Arkh,2018,90(8):27-32.
[14] Gadsby JE,Nipper AT,Faircloth HA,et al.Toll-like receptor and related cytokine mRNA expression in bovine corpora lutea during the oestrous cycle and pregnancy [J].Reprod Domest Anim,2017,52(3):495-504.
[15] Albalushi MS,Said EA,Hasson SS,et al.High levels of IgA antibodies to helicobacter pylori among Omani women during pregnancy and after delivery [J].Iran J Immunol,2016,13(2):114-123.